Skip to content Skip to footer
Subscribe Now
Pfizer New
NEWS

Pfizer Reports Topline P-III (HER2CLIMB-05) Trial Data of Tukysa (Tucatinib) in Metastatic Breast Cancer (MBC)

Shots: Pfizer has reported P-III (HER2CLIMB-05) trial data assessing Tukysa (n=326) vs PBO (n=328), both in combination with trastuzumab & pertuzumab, as a maintenance therapy for pts with HER2+ MBC following induction therapy in the 1L setting Trial met its 1EP with a significant improvement in the investigator-assessed PFS & showed favorable safety; data to…
October 15, 2025

Read more

John Strickler, Associate Professor of Medicine, Duke University School of Medicine, Shares Insights from the P-II Study at the 2022 ESMO World Congress on Gastrointestinal Cancer
VIEWPOINTS

John Strickler, Associate Professor of Medicine, Duke University School of Medicine, Shares Insights from the P-II Study at the 2022 ESMO World Congress on Gastrointestinal Cancer

Shots: John spoke about the results from the P-II MOUNTAINEER Trial evaluating its lead candidate in mCRPC He also talked about TUKYSA (tucatinib) in combination with trastuzumab as a potential treatment for mCRPC The interview gives a deeper understanding of Seagen’s vision of developing transformative cancer treatment options Smriti: Share the details (ROA, MOA & formulations)…
September 6, 2022

Read more